Significance
============

Stage III melanoma patients can have vastly different outcomes. Currently, for stage IIIc patients, the risk of progression and response to therapy cannot be predicted. Additional prognostic markers for accurate risk stratification are needed. We describe here the first proteome analysis of lymph node metastases from stage IIIc patients with poor and good survival. We have identified 84 proteins that change between the two survivor groups. Several identified markers were validated with high concordance using selected reaction monitoring mass spectrometry. The protein signatures obtained classify melanoma patients into the two prognostic groups and may aid prognostication of metastatic melanoma.

Introduction
============

The 5-yr survival for clinically localized melanoma (American Joint Committee on Cancer, AJCC stages I and II) ranges from 97 to 53%, while the prognosis for metastatic melanoma is poor with 5-yr survival rates ranging from 70 to 39% for patients with lymph node involvement (AJCC stage III) and 18 to 6% for patients with distant metastases (AJCC stage IV) ([@b2]). Patients with stage III disease can have vastly different outcomes, particularly those with bulky nodal metastases (AJCC stage IIIc). Some patients have long survival following current treatments, while others with an identical AJCC stage survive less than 6 months. Currently, prognosis based on histological and clinical factors is unsatisfactory for predicting risk of disease progression and response to adjuvant therapy. The difficulty in classification of melanoma into prognostic subgroups and selection of treatments is reflected in the failure to improve outcomes for advanced disease. Additional prognostic markers are needed to provide more accurate diagnosis and prognosis.

Histological and clinical factors used for diagnosis of melanoma are of limited use. Biomarkers could provide additional prognostic information based on the molecular mechanisms of transformation and disease progression. A systematic review summarizes the use of protein biomarkers visualized by immunohistochemistry to predict melanoma outcome ([@b40]). Gene expression profiling of melanoma has yielded an enormous amount of information leading to the definition of molecular signatures for disease progression ([@b23]; [@b26]; [@b52]), recurrence, and survival ([@b5]). For example, global gene expression profiling was used to classify AJCC stage IV melanomas into four subtypes associated with biological parameters such as pigmentation and immune response, with significant correlation to clinical outcomes ([@b29]). In addition, gene expression signatures can predict clinical outcomes in stage III melanoma patients ([@b28]). Recently, in a parallel study to this article, [@b34] reported that the presence of BRAF and NRAS mutations, and the absence of an immune-related transcriptome profile, predicted poor outcome in stage III melanoma patients. The phenotype of a cell or tissue correlates directly with protein levels and their post-translational modifications, but they may not correlate with mRNA levels ([@b22]). Several studies have sought to identify protein signatures associated with melanoma disease progression ([@b6]).

Proteomic analysis of melanoma samples from large patient cohorts is challenging and may be limited by lack of fresh tissue. Previous proteomic studies on melanoma have primarily used cell lines ([@b6]) that limit the clinical relevance. While a number of studies have analyzed serum proteomes to identify melanoma biomarkers ([@b15]; [@b36]), there have been few proteomic studies involving surgical specimens, most likely due to the limited access to adequate amounts of clinical samples. Histology-directed MALDI MS was used to identify differentially abundant proteins from 69 lymph node samples containing metastatic melanoma (stage III) and 17 control, tumor-free lymph nodes ([@b24]). Protein signatures were identified that enabled classification of tumor and normal lymph tissue. Despite extensive efforts using immunohistochemistry, gene expression, and protein profiling, there are few validated prognostic biomarkers that predict prognosis independently of more easily assessed clinical and pathologic parameters ([@b2]; [@b41]). Some studies suggest that the protein S-100B is of prognostic value for stage III melanoma ([@b31]), but only serum lactate dehydrogenase (LDH) has been validated as an independent prognostic factor for stage IV melanoma ([@b12]). Novel prognostic markers for routine diagnostic pathology are needed.

Here, we describe the first proteomic analyses of lymph node metastases from stage IIIc melanoma patients with poor and good survival outcomes. Complementary proteomic discovery platforms, two-dimensional fluorescence difference gel electrophoresis (DIGE), isobaric tags for relative and absolute quantitation (iTRAQ), and two-dimensional liquid chromatography coupled to tandem mass spectrometry (2DLC-MS/MS) were used to identify differentially abundant proteins between the survivor groups. Some of these potential prognostic markers were validated using selected reaction monitoring (SRM) mass spectrometry with an orthogonal method of protein quantitation. Protein signatures obtained classify melanoma patients into the two prognostic groups. Differentially abundant proteins identified here provide information on the molecular mechanisms associated with poor survival outcomes and, when independently validated, should enable more accurate risk stratification of AJCC stage III melanoma patients.

Results
=======

Difference gel electrophoresis and iTRAQ 2DLC-MS/MS analyses were performed on whole tissue extracts of lymph node melanoma metastases from AJCC stage IIIc patients with good (n = 19, \>4 yr survival post-resection) and poor (n = 14, died \<1 yr post-resection) survival outcomes (Tables S1 and S2). Differentially abundant proteins (84) with potential prognostic utility were identified. Of these proteins, 21 have been validated using SRM with high concordance between these analytical approaches.

DIGE analysis
-------------

A representative DIGE image is shown in Figure S1 with differentially abundant proteins indicated. On each analytical DIGE gel, more than 1000 protein spots were detected and 994 spots were matched across the nine gels. A total of 20 protein spots showed significant differences in protein abundance between the two prognostic groups (Student\'s t test P \< 0.05, Table S3). Protein spots were excised from preparative gels for identification by tryptic in-gel digestion and LC-MS/MS analysis. Following a Mascot database search of the ESI-MS/MS data, 19 of the 20 protein spots, belonging to 13 protein species, were identified. Protein spot 16 was of low abundance and not identified. Phosphoglycerate kinase 1 (spots 2, 10), glutathione S-transferase P (spots 5, 13), glyceraldehyde 3-phosphate dehydrogenase (spots 15, 20), tumor rejection antigen gp96 (spots 3, 19), and peptidyl-prolyl cis-trans isomerase (spots 7, 9 and 18) showed multiple spots, most likely due to post-translational or chemical (e.g., deamidation of asparagine) modifications leading to spot shifts in the gel.

iTRAQ 2DLC-MS/MS analysis
-------------------------

The summary of proteins, peptides, and spectra obtained from iTRAQ 2DLC-MS/MS analysis using ProteinPilot™ is presented in Table S4. The reproducibility of the iTRAQ 2DLC-MS/MS experiments was assessed using an internal control (iTRAQ 113), comprised of all samples and run in all six iTRAQ sets. The median Pearson\'s coefficient for the pairwise comparison between the sets was 0.76 (Table S5). A detailed list of proteins detected together with sequence coverage and the number of peptides matched is provided in Table S6. Quantitative iTRAQ 2DLC-MS/MS was performed using the detected peptide levels. After removing peptides with missing values, 8260 peptides were identified from merging the six 2DLC-MS/MS runs, corresponding to 2031 proteins. The number of proteins identified across 33 samples is presented in Figure S3. At 10% FDR (adjusted P-value \<0.1), 73 proteins were differentially abundant between poor and good prognosis patients (Table S7), 59 (81%) of which were significant at 5% FDR (adjusted P-value \<0.05) and 38 (52%) were significant at 1% FDR (adjusted P-value \<0.01). A heat map generated from iTRAQ-labeled, differentially abundant proteins shows clustering of melanoma patients with poor (\<1 yr) and good (\>4 yr) survival outcomes (Figure [1](#fig01){ref-type="fig"}).

![Hierarchical clustering for 73 differentially abundant proteins (10% false discovery rate (FDR)) for 33 melanoma patients. Proteins were identified using iTRAQ 2DLC-MS/MS (Table S7). Decreased (green) and increased (red) protein levels are shown. Patients with poor (\<1 yr, blue color) and good (\>4 yr, red color) survival outcomes have segregated as indicated by the red and blue bars above the heat map.](pcmr0027-1106-f1){#fig01}

Pathways and network analysis
-----------------------------

The Human Protein Reference Database (<http://www.hprd.org/>) was used to assign proteins to their primary cellular location and biological process. More than 80% of the differentially abundant proteins identified by DIGE and iTRAQ 2DLC-MS/MS are intracellular with only 5% assigned to plasma membranes and 12% to the extracellular space (Figure S4A). As shown in Figure S4B, the majority of proteins identified by DIGE and iTRAQ 2DLC-MS/MS are involved in metabolism: energy pathways (20%), protein metabolism (20%), cell communication and signal transduction (17%), cell growth and/or maintenance (11%), regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism (13%), immune response (6%), and apoptosis (2%). Key differences for the poor prognosis cohort include an increase in protein metabolism and regulation of nucleobase, nucleoside, nucleotide, and nucleic acid metabolism, and a decrease in cell communication/signal transduction proteins (Figure S4C,D). Of the five significant pathways identified by MetaCore™, four are involved in the immune response (Table S8; 1% FDR). Eight significant networks were generated, of which three were assigned to protein folding and three to immune response (Table S8; 1% FDR).

Verification of prognostic candidates and survival analysis
-----------------------------------------------------------

Nineteen prognostic candidates (accession numbers highlighted in Tables S3 and S7) were selected for validation based on the presence of proteotypic peptides and functional relevance to cancer progression. A further four proteins (ATP synthase subunit *β*, ATP-dependent RNA helicase DDX5, periostin, and T-complex protein 1 subunit zeta) were selected for SRM analysis due to their potential as prognostic markers (see Discussion). SRM analyses were performed using the original cohort (n = 33; Table S1) plus an additional 10 samples (Table S2). SRM measurements were highly reproducible across the replicates (median *R* = 0.85, Figure S5). The fold changes of proteins and P-values between the two prognostic groups, as well as the correlation of SRM measurements with iTRAQ data, are presented in Table [1](#tbl1){ref-type="table"}. Twenty-one proteins were differentially abundant between poor and good prognosis groups (P \< 0.05), while two proteins (LDHA and KRT9) had marginal significance (P \< 0.1; Table [1](#tbl1){ref-type="table"}). All proteins, with the exception of KRT9, were significant at the 10% FDR adjustment (Table [1](#tbl1){ref-type="table"}). The distribution of protein abundance levels across the patient cohorts is shown in Figures[2](#fig02){ref-type="fig"} and S6. The SRM results confirm the iTRAQ 2DLC-MS/MS findings, with high concordance between the two methods (Figure [3](#fig03){ref-type="fig"}); the median Pearson\'s coefficient for the analyses was 0.74, and for some proteins \>0.90 (Table [1](#tbl1){ref-type="table"}). Western blot analyses were performed on two proteins, confirming that protein changes observed by MS are also found using a different analytical platform. Consistent with 2DLC-MS/MS and SRM results, Western blotting showed increased levels of eukaryotic initiation factor 4A-I (P = 0.014) and decreased superoxide dismutase \[Mn\] (P = 0.099) in patients with poor prognosis (Figure S7).

###### 

Summary of SRM measurements from 33 AJCC stage III melanoma samples

  Acc. no[a](#tf1-1){ref-type="table-fn"}   Protein name                                                Gene name   FD[b](#tf1-2){ref-type="table-fn"} PP/GP   Unadjusted P-value[c](#tf1-3){ref-type="table-fn"}   Adjusted P-value[d](#tf1-4){ref-type="table-fn"}   Corr.[e](#tf1-5){ref-type="table-fn"}   mRNA FD[f](#tf1-6){ref-type="table-fn"} PP/GP
  ----------------------------------------- ----------------------------------------------------------- ----------- ------------------------------------------ ---------------------------------------------------- -------------------------------------------------- --------------------------------------- -----------------------------------------------
  Q15063                                    Periostin                                                   POSTN       1.68                                       0.000                                                0.001                                              0.85                                    −1.21
  P08238                                    Heat-shock protein HSP 90-*β*                               HSP90AB1    1.37                                       0.000                                                0.000                                              0.59                                    1.20
  P09874                                    Poly \[ADP-ribose\] polymerase 1                            PARP1       1.36                                       0.000                                                0.002                                              0.81                                    1.07
  P11142                                    Heat-shock cognate 71 kDa protein                           HSPA8       1.27                                       0.003                                                0.009                                              0.52                                    −1.29
  P17844                                    Probable ATP-dependent RNA helicase DDX5                    DDX5        1.22                                       0.000                                                0.001                                              0.48                                    −1.23
  P60842                                    Eukaryotic initiation factor 4A-I                           EIF4A1      1.21                                       0.002                                                0.007                                              0.66                                    −1.08
  P23526                                    Adenosyl homocysteinase                                     AHCY        1.19                                       0.001                                                0.003                                              0.75                                    1.07
  P12956                                    X-ray repair cross-complementing protein 6                  XRCC6       1.18                                       0.000                                                0.000                                              0.46                                    −1.04
  P13010                                    X-ray repair cross-complementing protein 5                  XRCC5       1.15                                       0.022                                                0.051                                              0.39                                    −1.04
  P00338                                    L-lactate dehydrogenase A chain                             LDHA        1.13                                       0.055                                                0.098                                              0.84                                    −1.04
  Q08211                                    ATP-dependent RNA helicase A                                DHX9        1.13                                       0.034                                                0.073                                              0.63                                    1.02
  Q99798                                    Aconitate hydratase, mitochondrial                          ACO2        1.12                                       0.040                                                0.083                                              0.54                                    1.09
  P40227                                    T-complex protein 1 subunit zeta                            CCT6A       1.12                                       0.043                                                0.083                                              0.64                                    −1.07
  P06576                                    ATP synthase subunit *β*, mitochondrial                     ATP5B       −1.17                                      0.013                                                0.035                                              0.93                                    1.06
  P35527                                    Keratin, type I cytoskeletal 9                              KRT9        −1.22                                      0.098                                                0.158                                              0.23                                    1.01
  P27797                                    Calreticulin                                                CALR        −1.26                                      0.003                                                0.008                                              0.69                                    −1.06
  Q9UL46                                    Proteasome activator complex subunit 2, PA28 *β*            PSME2       −1.26                                      0.048                                                0.090                                              0.77                                    −1.51
  P04179                                    Superoxide dismutase \[Mn\], mitochondrial                  SOD2        −1.33                                      0.022                                                0.051                                              0.84                                    −1.50
  P10909                                    Clusterin                                                   CLU         −1.36                                      0.001                                                0.003                                              0.97                                    −1.00
  Q06323                                    Proteasome activator complex subunit 1, PA28 *α*            PSME1       −1.37                                      0.000                                                0.001                                              0.86                                    −1.29
  O75367                                    Core histone macro-H2A.1                                    H2AFY       −1.41                                      0.001                                                0.003                                              0.74                                    −1.11
  P13796                                    Plastin-2 (L-Plastin)                                       LCP1        −1.56                                      0.000                                                0.000                                              0.90                                    −3.40
  Q9ULZ3                                    Apoptosis-associated speck-like protein containing a CARD   PYCARD      −1.70                                      0.000                                                0.000                                              0.80                                    −1.09

Accession numbers of proteins were from the Swiss-Prot database.

Positive fold difference represents higher levels in poor prognosis subjects, and negative fold difference represents higher levels in good prognosis subjects.

Unadjusted P-values.

False discovery rate is calculated using the function p.adjust in the Limma package based on Benjamini & Hochberg ([@b4]).

Pearson correlation of SRM values with those of iTRAQ 2DLC-MS/MS.

mRNA gene expression level was obtained using the corresponding data set (see ([@b34]) for full description of expression data).

GP, good prognosis; PP, poor prognosis.

![Scatter plots showing the distribution of protein levels in 33 lymph node melanoma metastases, verified by SRM. Each protein is represented by 2 peptides; (A) plastin-2, (B) apoptosis-associated speck-like protein containing a CARD, (C) heat shock protein HSP 90-beta, and (D) eukaryotic initiation factor 4A-I. The ordinate denotes the normalized logarithmic ratio of the sum of transitions from the indicated endogenous peptide to the sum of transitions of all samples to the corresponding peptide analyzed, followed by RUV adjustment. The abscissa represents patient survival in months. Patients with poor survival (\<1 yr) are indicated in green, and patients with good survival (\>4 yr) are indicated in blue. The red line is the average log ratio of the peptide. P-values of individual peptides were calculated using moderated t test. The experiment was performed in duplicate, circles represent replicate 1, and stars are replicate 2.](pcmr0027-1106-f2){#fig02}

![Correlation plots of differentially abundant proteins assessed using iTRAQ 2DLC-MS/MS and SRM from 33 AJCC stage III melanoma patients. The ordinate denotes the log ratio of the protein abundance level using iTRAQ 2DLC-MS/MS analysis, and the abscissa is the log ratio of the protein level assessed by SRM. Abbreviations: GP, good prognosis (red); PP, poor prognosis (blue).](pcmr0027-1106-f3){#fig03}

Proteomic patterns as assessed by SRM (Table [1](#tbl1){ref-type="table"}) were used to construct Kaplan--Meier survival curves for patients with good and poor prognosis (Figure [4](#fig04){ref-type="fig"}), with a 24% prediction error. The Kaplan--Meier plot for the cross-validated predicted outcomes from the initial 33 AJCC stage III melanoma patients shows wide separation of patient groups (P = 0.019). Significant (P = 0.02) separation of good and poor prognosis groups was also demonstrated using Kaplan--Meier plots for an independent predicted outcome generated from the 10 independent melanoma samples. The survival times were less strict for these additional 10 samples with median survival of 1.1 yr for poor and 3.6 yr for good prognosis groups. The clear separation of the two prognostic groups indicates the robustness of our candidate markers.

![Kaplan--Meier survival curves for patients with good and poor prognosis based on SRM data (Table [1](#tbl1){ref-type="table"}). (A) Kaplan--Meier curve for the cross-validated predicted outcomes from the initial 33 AJCC stage III melanoma patients. (B) Kaplan--Meier plot for an independent predicted outcome generated from the 10 independent melanoma samples. A log-rank test was used to test for significance in survival between the prognostic groups (P \< 0.05). Abbreviations: GP, good prognosis; PP, poor prognosis.](pcmr0027-1106-f4){#fig04}

Discussion
==========

The AJCC melanoma staging system stratifies patients into heterogeneous groups, with wide variability in outcomes and responses to therapy. More accurate prognostic indicators are needed for metastatic melanoma patients. Considerable efforts are focused on developing criteria for treatment selection, based on individual cancer molecular profiles. While several studies have attempted to identify gene and mRNA signatures for survival in stage III melanoma, proteomic analyses have been limited. Identification of differentially abundant proteins between different prognostic groups will aid the development of prognostic indicators for stage III melanoma and enhance understanding of the molecular mechanisms associated with poor outcomes.

A total of 84 proteins (73 from iTRAQ 2DLC-MS/MS, 13 from DIGE, two common to both) were identified as differentially abundant between the poor and good prognosis cohorts. Many of the identified proteins are highly abundant heat-shock, metabolic, and structural proteins (Table S7, Figure S4). Sample complexity is a critical factor for peptide identification and quantitation. Due to the large number of proteotypic peptides in tissue samples, only a small subset of all peptides in a sample (the most abundant peptides) can be identified and quantified in a single MS run. Prefractionation using SCX chromatography reduced sample complexity to some extent and enabled quantitation of some low abundance proteins (e.g., STAT1, SUB1).

It is not surprising that only two proteins (calreticulin and collagen type 1 *α*1) were common to both proteomics platforms, as iTRAQ coupled to LC-MS/MS is complementary to DIGE ([@b60]). Similarly, others have found a low correlation between DIGE and iTRAQ 2DLC-MS/MS ([@b32]). Poor prognosis patients are characterized by increased levels of proteins involved in protein metabolism/folding, nucleic acid metabolism, angiogenesis, deregulation of cellular energetics, and methylation processes, and decreased levels of proteins involved in apoptosis and immune response (Figure S4).

Several proteins identified here were previously associated with melanoma prognosis. L-lactate dehydrogenase A chain (*LDHA*) and L-lactate dehydrogenase B chain (*LDHB*) are more abundant in patients with poor prognosis (Tables[1](#tbl1){ref-type="table"} and S7). LDH was reported as the strongest independent prognostic factor for stage IV melanoma ([@b12]). The lower abundance of histone H2A (*H2AFY*) in poor prognosis patients (Tables[1](#tbl1){ref-type="table"} and S7) is consistent with the results of [@b24], who found that decreased levels of histones H4, H3, and H2B correlated with poor survival of patients with AJCC stage III melanoma. L-plastin (*LCP1*) and signal transducer and activator of transcription 1 (*STAT1*) also showed significant differential mRNA levels in our parallel transcriptomics study ([@b34]). This concordance rate may be explained by a predominance of mRNAs encoding membrane proteins identified in the transcriptomics study, whereas the proteomics approaches used here predominantly isolated intracellular proteins (Figure S4A). Proteomic analyses of total cell or tissue lysates typically identify only a handful of membrane proteins; the amphiphilic nature, heterogeneity, and relative low abundance of plasma membrane proteins likely contribute to an under-representation in global proteome analyses. Furthermore, mRNA is not the functional end point of gene expression, and mRNA abundance was previously shown as a poor indicator of corresponding protein levels ([@b22]).

The differences in protein abundance between the poor and good prognosis groups are subtle. While iTRAQ labeling enables quantification of large numbers of proteins, it has a low dynamic range and tends to underestimate the actual abundance changes of proteins ([@b53]). In addition, the proteins identified here may originate from different cell types in the tissue sample (melanoma, leukocytes, stroma). Analysis of protein abundances in specific cell subpopulations (e.g., by microdissection) may reveal higher fold-changes between the two prognostic groups. Despite the relatively low abundance changes of individual proteins (Table [1](#tbl1){ref-type="table"}), the combined protein signature does classify patients into prognostic groups using the Kaplan--Meier estimate (Figure [4](#fig04){ref-type="fig"}) for the original 33 samples and the additional 10 samples. The functions of some of the identified proteins and their roles in cancer progression and prognosis are described below.

Increased levels of chaperones, DNA repair proteins, and RNA helicases in poor prognosis patients
-------------------------------------------------------------------------------------------------

Cytosolic heat-shock protein 90 kDa, beta (*HSP90AB1*), its ER paralogue, tumor rejection antigen gp96 (*HSP90B1*), and heat-shock cognate 71 kDa protein (*HSPA8*), are found at higher levels in poor prognosis patients (Tables[1](#tbl1){ref-type="table"}, S3 and S7). Many proteins required for melanoma initiation and progression, including mutated BRAF, CRAF, IGF1R, cyclin D1, CDK4, and AKT, are known clients of HSP90 ([@b19]). HSP90 was identified as a progression marker in primary melanomas, with high levels associated with higher Clark levels and increased Breslow thickness ([@b35]). Several subunits of T-complex protein 1 (TCP-1) were found at higher abundance in poor prognosis patients (Tables[1](#tbl1){ref-type="table"} and S7). Increased expression of TCP-1 subunit zeta (*CCT6A*) may be associated with melanoma drug resistance ([@b48]).

Increased levels of poly(adenosine diphosphate-ribose) polymerase 1 (*PARP1*) in lymph node metastases from poor prognosis patients are in accordance with previous observations where overexpression of PARP1 was proposed as a molecular marker of aggressive cutaneous melanoma ([@b44]). In addition, PARP1 was associated with melanoma development ([@b61]), tumor aggressiveness, and chemoresistance ([@b49]). Eukaryotic initiation factor 4A1 (DDX2A, gene *EIF4A1*), probable ATP-dependent RNA helicase DDX5 (*DDX5*), and ATP-dependent RNA helicase A (DDX9, gene *DHX9*) are 3 RNA helicases present at higher levels in poor prognosis patients (Table [1](#tbl1){ref-type="table"}). DDX2A (eIF4A1) mRNA is consistently overexpressed in human melanoma cells in vitro ([@b13]). Antisense-mediated downregulation of DDX2A in melanoma cell lines resulted in inhibition of proliferation, suggesting that DDX2A may play a role in melanoma tumorigenesis ([@b14]). DDX5 is involved in alternative splicing of the proto-oncogene c-H-ras ([@b21]) and is elevated in cutaneous squamous cell carcinoma ([@b59]). DDX9 is cleaved early in apoptosis, suggesting that loss of its function might contribute to induction of apoptosis ([@b46]).

Deregulation of mitochondrial enzymes in poor prognosis patients
----------------------------------------------------------------

One of the hallmarks of aggressive malignancies is defective mitochondrial electron transport. Here, several mitochondrial proteins (12%, Figure S4A) were deregulated in poor prognosis patients. Mitochondrial ATP synthase subunit beta (*β*-F1-ATPase, gene *ATP5B*) and superoxide dismutase \[Mn\] (*SOD2*) are lower while aconitate hydratase (*ACO2*) is higher in patients with a poor prognosis (Table [1](#tbl1){ref-type="table"}). SOD2 expression is decreased in many cancers and has been implicated as a candidate tumor suppressor gene in human melanoma ([@b9]). Low *β*-F1-ATPase levels and therefore a diminished bio-energetic capability of the tumor are associated with poor prognosis as assessed in large cohorts of patients with colorectal ([@b33]), lung ([@b11]), and breast ([@b25]) cancer. Significant findings of different SOD2, ACO2, and *β*-F1-ATPase levels in melanoma patients with poor survival warrant further investigation for their potential use as biomarkers.

Escape from immuno-surveillance in poor prognosis patients
----------------------------------------------------------

Metastatic melanoma is highly immunogenic. The majority of the molecular pathways and networks associated with the proteins identified here (Table S8) are involved in immune response, perhaps indicative of evasive immune strategies in patients with poor outcomes. Several proteins involved in the immune response were reduced in poor prognosis patients. Changes in calreticulin (*CALR*) levels, a component of the antigen-processing machinery (APM), may affect immune response to metastatic melanoma ([@b1]). Intracellular calreticulin may contribute to immune evasion through reduction of major histocompatibility complex (MHC) class I antigen presentation ([@b8]), whereas cell surface calreticulin is required for the interpretation of a cell death response by antigen-presenting cells ([@b37]). IFN-*γ* exposure of melanoma cells increased calreticulin cell surface accessibility ([@b10]) that has been associated with increased phagocytosis of melanoma cells by macrophages, an antitumoral immune response ([@b39]). Depleted calreticulin in lymph node metastases from poor prognosis patients could contribute to mechanisms by which tumor cells escape immunosurveillance. Subcellular localization of calreticulin in lymph node tumors is required to determine its role in antimelanoma immunity.

The L-plastin gene is activated in most human cancer cells ([@b38]); however, L-plastin is also expressed at high levels in leukocytes and has important functions in innate and adaptive immunity ([@b43]). L-plastin was shown to regulate chemokine-induced lamellipodia formation, polarization, and migration of human T-lymphocytes ([@b16]). The reduced levels of L-plastin observed in this study in poor prognosis patients may indicate reduced numbers of leukocytes and, subsequently, immune reactivity.

Proteasome activator complex subunit 1 (PA28*α*, gene *PSME1*) and proteasome activator complex subunit 2 (PA28*β*, gene *PMSE2*), other proteins that might alter the immune response to melanoma cells, were lower in patients with poor outcomes. Proteasomes, the major proteolytic machinery in the cytosol, generate most of the MHC class I-presented peptides ([@b30]) recognized by CD8^+^ cytotoxic T lymphocytes. PA28*α* and PA28*β* are two IFN-*γ*-inducible subunits of proteasome activator PA28 that enhance antigen presentation ([@b27]; [@b56]). The generation of a cytotoxic T-lymphocyte epitope on melanoma cells is dependent on the function of PA28 ([@b45]). Moreover, PA28 function is particularly relevant for the generation of normally poorly excised peptide products ([@b50]), indicating that PA28 is able to alter the immunophenotype of a cell. The depletion of calreticulin, L-plastin, PA28*α*, and PA28*β* suggests that the immune response may be impaired in lymph node metastases from patients with reduced survival. These observations are mirrored by the recent parallel study by [@b34] that highlights a significant association of immune response genes, T-cell receptor signaling, and IFN-*γ* signaling with survival outcomes of patients with AJCC stage IIIc metastatic melanoma.

Other functions
---------------

Collagen type I *α*I (*COL1A1*) was identified at higher abundance from both DIGE and 2DLC-MS/MS analyses in patients with poor prognoses (Tables S3 and S7). Type I collagen is synthesized by tumor-associated non-transformed fibroblasts and demarcates the transition from non-invasive keratinocytic intra-epidermal neoplasia to invasive cutaneous squamous cell carcinoma ([@b57]). In addition, collagen type I contributes to angiogenesis and the development of deeply invasive cutaneous melanoma ([@b58]). Periostin (*POSTN*), present at higher abundance in patients with shorter survival times (Table [1](#tbl1){ref-type="table"}), activates the Akt/PKB signaling pathway, leading to enhanced cellular survival ([@b3]) and angiogenesis ([@b42]). Periostin expression is unchanged in primary disease, but overexpressed in 60% of melanoma liver or lymph node metastases, with melanoma cells and the surrounding stroma identified as sources of periostin ([@b51]). In addition, periostin levels correlate with increased primary tumor thickness and the development of metastatic disease ([@b51]). The high levels of collagen type I *α*I and periostin detected here (Tables[1](#tbl1){ref-type="table"} and S7) may increase tumor aggressiveness, leading to poor survival outcomes in stage IIIc patients by, for example, enhancing angiogenesis and melanoma cell survival.

S-Adenosylhomocysteinase (SAHH, gene *AHCY*), the key enzyme in the maintenance of methylation homeostasis, is higher in patients with poor prognosis (Tables[1](#tbl1){ref-type="table"} and S7). More than 70 genes are hypermethylated in cutaneous melanoma ([@b55]). Regional hypermethylation was increased with advanced clinical stage, and the methylation status of MINT31 (methylated in tumor loci 31) was associated with disease outcome in stage IIIc patients ([@b47]). The increased levels of SAHH may indicate deregulated methylation in poor prognosis patients.

Apoptosis-associated speck-like protein containing a CARD (ASC, gene *PYCARD*) was found in lower abundance in the poor prognosis cohort (Tables[1](#tbl1){ref-type="table"} and S7). Importantly, pro-apoptotic ASC is subject to aberrant DNA methylation and epigenetic silencing in a number of different tumor types, including melanoma ([@b20]). ASC is high in benign melanocytic nevi and markedly reduced in human melanoma cell lines and clinical specimens ([@b20]). Decreased abundance of ASC may confer a survival advantage for melanoma cells by allowing them to escape from apoptosis.

In summary, we have performed the first comprehensive proteomic profiling of melanoma lymph node metastases in AJCC stage IIIc patients with poor and good survival outcomes. Deregulated proteins in poor prognosis patients may provide signatures for prognosis and offer insights into important aspects of melanoma biology. Proteins verified by SRM are able to classify stage IIIc melanoma patients into prognostic subgroups (P \< 0.02). The protein markers identified here complement the molecular signatures described by [@b34]. Further assessment of these candidate proteins using robust methodology and statistics will be necessary to evaluate their potential to predict outcomes for patients with AJCC stage IIIc metastatic melanoma.

Methods
=======

Clinical specimens
------------------

Melanoma lymph node metastases were obtained from the Melanoma Institute Australia (BioSpecimen Bank, Sydney South West Area Health Service institutional ethics review committee (RPAH Zone) Protocols No. X08-0155/HREC 08/RPAH/262, X11-0023/HREC 11/RPAH/32 and X07-0202/HREC/07/RPAH/30). With informed consent, samples of melanoma lymph node metastases from AJCC stage IIIc patients undergoing surgery at the Melanoma Institute Australia (Sydney, NSW, Australia) were collected and banked. Quantitative iTRAQ 2DLC-MS/MS and SRM analyses were performed on 33 melanoma lymph node tumors from patients with good prognosis (19 samples, \>4 yr survival post-resection) and poor prognosis (14 samples, died \<1 yr post-resection). The proteomic analyses presented here use the same patient selection criteria and many of the samples that were analyzed in the parallel transcriptomics study ([@b34]). Due to larger quantities of protein required for DIGE analysis, we analyzed a subset of these samples (n = 18). Providing sufficient material was present, priority was given to samples with the shortest and longest survival times for the poor and good prognosis cohorts, respectively. One sample (PP4) was removed from the DIGE analysis, as this patient died from causes other than melanoma. Clinico-pathologic characteristics of the 33 AJCC stage IIIc melanoma patients and their tumors are summarized in Tables S1 and S2. There was limited access to frozen lymph node metastases from patients from the extreme ends of the survival spectrum (poor: \<1 yr, median survival time 0.5 yr; good: \>4 yr, median survival time 8.1 yr). For validation by SRM using an independent cohort, 10 additional samples with less strict survival times were used. For poor prognosis (n = 6), median and mean survival times were 1.1 and 1.3 yr (SD = 0.3, range: 1.0--2.0 yr), respectively. For good prognosis (n = 4), median and mean survival times were 3.6 and 3.3 yr (SD = 0.8, range: 2.1--4.0 yr), respectively.

For preparation of protein lysates, frozen melanoma lymph node tumors were ground to a powder with liquid nitrogen and solubilized with 7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 65 mM DTT, 2 mM TBP, and 40 mM Tris base supplemented with protease inhibitors. Lysates were sonicated three times on ice using a step tip probe at 20% cycle intensity for 10 s (Ultrasonics Model W-225R; Ultrasonics, Inc., Plainview, NY, USA) and placed on ice for 30 s between each sonication. Protein lysates were centrifuged (16 000 *g*, 15 min, 4°C), and stocks stored at −80°C. iTRAQ labeling and 2DLC-MS/MS (Appendix S1), DIGE analysis, protein function and network analysis (Appendix S2), and SRM analysis (Appendix S3) are described in Supporting Information.

iTRAQ 2DLC-MS/MS data analysis
------------------------------

To identify differentially abundant proteins between poor and good prognosis groups, the following statistical analysis was carried out. All peptide expression ratios from the iTRAQ 2DLC-MS/MS analysis were transformed to logarithm (base 2) values. Here, a twofold increase or decrease is reported as 1 or −1, respectively. Peptides detected in less than 25% of samples were removed prior to the analysis (Figure S2). For each protein, a fixed effect model can be written aswhere *j* denotes the subject and *k* the number of peptide observations for each subject. The vector *Y* represents log ratios from different subjects, *μ* represents the mean, and the parameter T is the parameter of interest, which in this case is the true fold difference between the good and poor prognosis groups for the protein under consideration. The parameter *Pe*~*k*~ is the *k*^*th*^ peptide effect that is the difference between the fold change of the *k* peptide and the average over all peptides, and the symbol *ε* denotes the error. Our main goal was to estimate T for all identified proteins. This model selects for proteins that are differentially expressed between good and poor prognosis groups adjusting for mean differences between individual peptides within each protein. Candidate protein sets were selected by controlling for 10% FDR, which is equivalent to an adjusted P-value of 0.1. In practice, these models are fitted using functions in [r/bioconductor]{.smallcaps} software ([@b18]). The heat map from protein expression data was constructed using the function 'heatmap.2' in [r]{.smallcaps} that uses a Euclidean distance metric. The MS/MS spectra of differentially abundant proteins were manually inspected for correctness.

SRM data analysis
-----------------

The SRM data files (\*.wiff) were imported into [skyline]{.smallcaps} software, manually accessed for quality and exported for statistical analysis. Further manual inspection was performed to determine the inclusion or exclusion of each peptide for downstream analysis. The level of a peptide was summarized based on adding up intensity levels from all transitions from endogenous peptides, and a RUV random normalization was used ([@b17]). For each protein, a similar fixed effect model (as for the iTRAQ 2DLC-MS/MS data) was used written aswhere *j* denotes the subject, and *k* the number of peptide observations for each subject. The vector *Z* represents normalized log ratios observed in SRM experiments from different subjects, *μ* represents the mean, and the parameter *T* represents fold differences between good and poor prognosis for the protein under consideration. The parameter *Pe*~*k*~, represents the *k*^*th*^ peptide effect, *R*~*l*~ represents the *l*^*th*^ run (in this case, two independent runs of the SRM experiment exist for each protein), and the symbol *ε* denotes the error. For proteins with only one peptide, the modelwas used, equivalent to performing a t test between poor and good prognosis groups adjusting for differences between the two replicates. In addition, the Pearson\'s correlation coefficient between iTRAQ and SRM data for each protein was calculated. Statistical analyses were performed in the [r]{.smallcaps} statistical environment.

Survival analysis
-----------------

Survival modeling was performed to classify patients into two risk groups. All samples (the initial 33 and 10 additional independent samples) were combined and preprocessed together. Missing values were imputed based on KNN imputation implemented in the [r]{.smallcaps} package 'imputation' ([@b54]). Data were standardized (mean centered) at the peptide level and averaged to form protein level expression. Focusing on the SRM data, we selected all 23 proteins from the SRM analysis (Table [1](#tbl1){ref-type="table"}) and assessed the prognostic capacity. Using 'C classification' and linear kernel, a linear support vector machine (SVM) model based on the implementation in 'e1071' [r]{.smallcaps} package (Chang and Lin, Initial version: 2001, last updated: March 4, 2013) was applied to the initial set of 33 patient samples. The average of 100 sets of fivefold cross-validation error rate was calculated. We constructed Kaplan--Meier curves for the cross-validated predicted outcomes from the initial 33 patients. A log-rank test was used to test for significance in survival between the prognostic groups (P \< 0.05). In addition, an independent predicted outcome was generated from the additional 10 samples and a corresponding KM plot generated (for details see Appendix S3).
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